RBC Capital Maintains Outperform on Enviva, Raises Price Target to $85
RBC Capital analyst Elvira Scotto maintains Enviva (NYSE:EVA) with a Outperform and raises the price target from $78 to $85.
JP Morgan Maintains Neutral on Enviva, Raises Price Target to $76
JP Morgan analyst Mark Strouse maintains Enviva (NYSE:EVA) with a Neutral and raises the price target from $70 to $76.
Enviva Partners Q4 Adj. EBITDA (Recast Presentation) $55.1M vs $42.1M In Same Qtr. Last Year Sales $276.30M Miss $332.02M Estimate; Reaffirms Guidance
Enviva Partners (NYSE:EVA) reported quarterly sales of $276.30 million which missed the analyst consensus estimate of $332.02 million by 16.78 percent. This is a 0.36 percent decrease over sales of $277.31 million the
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Earnings Outlook For Enviva Partners
Enviva Partners (NYSE:EVA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement.
Analysts estimate that Enviva Partners will report an earnings per share (EPS) of $0.26.
Enviva’s Ex-Dividend Date Is Thursday, Here’s What You Need To Know
Thursday marks the last chance for investors to receive the next dividend payout from Enviva (NYSE:EVA).
Enviva Announces MOU With U.S. Customer; Terms Not Disclosed
Enviva Announces MOU With U.S. Customer, Provides Updates to Business and Sales Pipeline, and Accelerates Capacity Expansions
Enviva Inc. (NYSE:EVA) ("Enviva," "we," "us," or
What 5 Analyst Ratings Have To Say About Enviva
Over the past 3 months, 5 analysts have published their opinion on Enviva (NYSE:EVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Raymond James Maintains Outperform on Enviva, Raises Price Target to $77
Raymond James analyst Pavel Molchanov maintains Enviva (NYSE:EVA) with a Outperform and raises the price target from $75 to $77.